Clinical Trials

Studies Evaluating INH/Rifapentine Underway

Published in TB and Outbreaks Week, April 22nd, 1996

As of February 1996 more than 250 patients had been enrolled in a clinical trial comparing twice weekly isoniazid and rifampin to once weekly isoniazid and rifapentine, according to a report from the U.S. Centers for Disease Control and Prevention's (CDC) Division of TB Elimination.

An update on USPHS Study 22, also known as the Rifapentine Clinical Trial, was published in the CDC's winter 1996 TB Notes.

The controlled, randomized, open-label trial is now underway to compare the efficacy and safety of the two regimens.

Regimen 1 consists of standard twice-weekly therapy with high-dose isoniazid (900 mg) and rifampin (600 mg). ...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (1996-04-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry